Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
NCT06729593 · View on ClinicalTrials.gov ↗
Study Summary
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.
Conditions Studied
Interventions
- DRUG Corticosteroid
- BIOLOGICAL Remdesivir
- BIOLOGICAL Remdesivir Placebo
Study Locations (20)
California
- UCSF Fresno (Site 203-005), 155 N. Fresno Street — Fresno
- VA Loma Linda Healthcare System (Site 074-017), 11201 Benton Street — Loma Linda
- Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Boulevard — Los Angeles
- Ronald Reagan UCLA Medical Center (Site 203-002), 757 Westwood Plaza — Los Angeles
- UCSF Medical Center at Mount Zion (Site 203-007), 1600 Divisadero St. — San Francisco
- UCSF Medical Center (Site 203-001), Moffit-Long Hospital, 505 Parnassus Ave. — San Francisco
- Stanford University Hospital & Clinics (Site 203-003), 300 Pasteur Dr. — Stanford
New York
- Mount Sinai Medical Center (Site 301-012), Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place — New York
- Columbia University Irving Medical Center (Site 301-027), 177 Fort Washington Ave. — New York
- Montefiore Medical Center - Moses Hospital (Site 206-001), 111 E. 210th Street — The Bronx
- Montefiore Medical Center - Weiler campus (Site 206-003), 111 E. 210th Street — The Bronx
Colorado
- University of Colorado Hospital (Site 204-001), 12605 E. 16th Avenue — Aurora
- Denver Health Medical Center (Site 204-004), 780 Delaware Street, Pavilion B — Denver
District of Columbia
- MedStar Health Research Institute (Site 009-021), 110 Irving St., NW. — Washington D.C.
- Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW. — Washington D.C.
Massachusetts
- Massachusetts General Hospital (Site 202-002), 55 Fruit Street — Boston
- Baystate Medical Center (Site 201-001), Critical Care Research, 759 Chestnut Street — Springfield
Arizona
- Banner University Medical Center Tucson (Site 206-004), 1625 N. Campbell Avenue — Tucson
Georgia
- Emory University (Site 301-008), Bldg. A, Suite 2236, 1365 Clifton Rd., NE. — Atlanta
North Carolina
- Duke University Hospital (Site 301-006), 2301 Erwin Road — Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2022-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06729593
The ClinicalTrials.gov registry entry for NCT06729593 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 3 interventions — of which Corticosteroid is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06729593 reports 20 study locations spanning 8 distinct geographic areas — top geographies include California, New York, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06729593 about?
NCT06729593 is a clinical study titled "Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)". This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus curr...
What is the current status of trial NCT06729593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2021-04-20. Estimated completion is 2022-11-20.
What conditions does trial NCT06729593 study?
This clinical trial studies the following conditions: Covid19. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06729593?
The interventions under investigation include: Corticosteroid (DRUG), Remdesivir (BIOLOGICAL), Remdesivir Placebo (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06729593?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06729593 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.